Treatment Intent Frequency and number of cycles Monitoring Parameters pre-treatment  Intent  Frequency and number of cycles  • Virology screening: All new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion.  • Monitor FBC, LFT's and U&E's prior to each cycle (day 8 FBC only).  • If WBC >3 and neuts 1.0-1.5 and PLT >/=100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo.  • If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.  • Hepatic impairment: in patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin >2 x ULN and ALT/AST >5 x ULN) consider 66% of original dose.  • Renal impairment: no recommended dose reduction.  • Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to r/=grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.  • Common drug interactions (for comprehensive list refer to BNF/SPC):  • Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.  • Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.  • For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient	Indication	NSCLC					
Palliative   Intent							
Repeat every 21 days   Maximum of 6 cycles	Treatment						
Repeat every 21 days Maximum of 6 cycles  (vcles  Monitoring Parameters pre-treatment  • Virology screening: All new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion.  • Monitor FBC, LFT's and U&E's prior to each cycle (day 8 FBC only).  • If WBC>3 and neuts 1.0-1.5 and PLT >=100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >1.5 and PL		raillative					
Maximum of 6 cycles  Virology screening: All new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion.  Monitor FBC, LFT's and U&E's prior to each cycle (day 8 FBC only).  If WBC >3 and neuts 1.0-1.5 and PLT >/=100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo on If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.  Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin >2 x ULN and ALT/AST >5 x ULN) consider 66% of original dose.  Renal impairment: no recommended dose reduction.  Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to   /=grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.  Common drug interactions (or vinorelbine).  Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.  Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.  Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.  For oral self-administration: refer to local Trust policy on oral anti-cancer medi		Reneat every 21 days					
Monitoring Parameters pre-treatment  • Virology screening: All new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion.  • Monitor FBC, LFT's and U&E's prior to each cycle (day 8 FBC only).  • If WBC >3 and neuts 1.0-1.5 and PLT >/=100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo OR If neuts >1.5 and PLT >1.5	• •						
<ul> <li>Virology screening: All new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion.</li> <li>Monitor FBC, LFT's and U&amp;E's prior to each cycle (day 8 FBC only).</li> <li>If WBC &gt;3 and neuts 1.0-1.5 and PLT &gt;/=100 proceed with chemo OR If neuts &gt;1.5 and PLT &gt;100 proceed with chemo.</li> <li>If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.</li> <li>Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin &gt;2 x ULN and ALT/AST &gt;5 x ULN) consider 66% of original dose.</li> <li>Renal impairment: no recommended dose reduction.</li> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to  </li> <li>✓ Egrade 1.</li> <li>NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they s</li></ul>		Maximum of a cycles					
screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion.  Monitor FBC, LFT's and U&E's prior to each cycle (day 8 FBC only).  If WBC >3 and neuts 1.0-1.5 and PLT >/=100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo.  If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.  Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin >2 x ULN and ALT/AST >5 x ULN) consider 66% of original dose.  Renal impairment: no recommended dose reduction.  Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to  /=grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.  Common drug interactions (for comprehensive list refer to BNF/SPC):  Strong (YP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.  Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.  Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.  For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.  Driving: Patients should be advised to be	-	Virology screening: All new nationts referred for systemic anti-cancer treatment should be					
previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion.  Monitor FBC, LFT's and U&E's prior to each cycle (day 8 FBC only).  If WBC >3 and neuts 1.0-1.5 and PLT >/=100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo.  If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.  Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin >2 x ULN and ALT/AST >5 x ULN) consider 66% of original dose.  Renal impairment: no recommended dose reduction.  Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to =grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.  Common drug interactions (for comprehensive list refer to BNF/SPC):  Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.  Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.  Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.  For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.  Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</th <th>_</th> <th></th>	_						
and C. Further virology screening will be performed following individual risk assessment and clinician discretion.  Monitor FBC, LFT's and U&E's prior to each cycle (day 8 FBC only).  If WBC >3 and neuts 1.0-1.5 and PLT >/=100 proceed with chemo OR If neuts >1.5 and PLT >100 proceed with chemo.  If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.  Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin >2 x ULN and ALT/AST >5 x ULN) consider 66% of original dose.  Renal impairment: no recommended dose reduction.  Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to /-grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.  Common drug interactions (for comprehensive list refer to BNF/SPC):  Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.  Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.  Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.  For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.  Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.		· · · · · · · · · · · · · · · · · · ·					
<ul> <li>clinician discretion.</li> <li>Monitor FBC, LFT's and U&amp;E's prior to each cycle (day 8 FBC only).</li> <li>If WBC &gt;3 and neuts 1.0-1.5 and PLT &gt;/=100 proceed with chemo OR If neuts &gt;1.5 and PLT &gt;100 proceed with chemo.</li> <li>If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.</li> <li>Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin &gt;2 x ULN and ALT/AST &gt;5 x ULN) consider 66% of original dose.</li> <li>Renal impairment: no recommended dose reduction.</li> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to </li> <li>/=grade 1.</li> <li>NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>	pre-treatment						
<ul> <li>Monitor FBC, LFT's and U&amp;E's prior to each cycle (day 8 FBC only).</li> <li>If WBC &gt;3 and neuts 1.0-1.5 and PLT &gt;/=100 proceed with chemo OR If neuts &gt;1.5 and PLT &gt;100 proceed with chemo.</li> <li>If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.</li> <li>Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin &gt;2 x ULN and ALT/AST &gt;5 x ULN) consider 66% of original dose.</li> <li>Renal impairment: no recommended dose reduction.</li> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to /=grade 1.</li> <li>NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
<ul> <li>If WBC &gt;3 and neuts 1.0-1.5 and PLT &gt;/=100 proceed with chemo OR If neuts &gt;1.5 and PLT &gt;100 proceed with chemo.</li> <li>If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.</li> <li>Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin &gt;2 x ULN and ALT/AST &gt;5 x ULN) consider 66% of original dose.</li> <li>Renal impairment: no recommended dose reduction.</li> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to  /=grade 1. NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated. Common drug interactions (for comprehensive list refer to BNF/SPC): Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine. Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity. Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken. For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet. Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
proceed with chemo.  If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.  Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin >2 x ULN and ALT/AST >5 x ULN) consider 66% of original dose.  Renal impairment: no recommended dose reduction.  Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to  _grade 1. NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated. Common drug interactions (for comprehensive list refer to BNF/SPC): Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine. Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity. Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken. For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet. Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.							
<ul> <li>If blood parameters not met defer day 1 chemo for 1 week, or omit day 8. Consider dose reduction.</li> <li>Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin &gt;2 x ULN and ALT/AST &gt;5 x ULN) consider 66% of original dose.</li> <li>Renal impairment: no recommended dose reduction.</li> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to  <li>NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </li></ul>							
<ul> <li>Hepatic impairment: In patients with mild to moderate liver impairment no dose adjustment is needed. Severe (bilirubin &gt; 2 x ULN and ALT/AST &gt; 5 x ULN) consider 66% of original dose.</li> <li>Renal impairment: no recommended dose reduction.</li> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to  </li> <li>/=grade 1.</li> <li>NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
<ul> <li>needed. Severe (bilirubin &gt;2 x ULN and ALT/AST &gt;5 x ULN) consider 66% of original dose.</li> <li>Renal impairment: no recommended dose reduction.</li> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to <!--=grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li--> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </li></ul>							
<ul> <li>Renal impairment: no recommended dose reduction.</li> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to <!--=grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li--> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </li></ul>							
<ul> <li>Dose Modification: Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to <!--=grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li--> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </li></ul>							
or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to =grade 1.  NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.  Common drug interactions (for comprehensive list refer to BNF/SPC):  Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.  Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.  Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.  For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.  Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</th <th></th> <th></th>							
<ul> <li><!--=grade 1.</li--> <li>NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </li></ul>							
<ul> <li>NB: The dose escalation of vinorelbine was removed from the protocol as agreed by the Lung NOG (May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
<ul> <li>(May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m² from cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
<ul> <li>cycle 3 where the consultant considers this to be clinically indicated.</li> <li>Common drug interactions (for comprehensive list refer to BNF/SPC):</li> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>		(May 2024). There may be exceptions where the vinorelbine dose is escalated to 80mg/m <sup>2</sup> from					
<ul> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
<ul> <li>Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) should be avoided, as this may decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>		Common drug interactions (for comprehensive list refer to BNF/SPC):					
<ul> <li>decrease blood concentrations of vinorelbine.</li> <li>Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
<ul> <li>be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
<ul> <li>be avoided as this will result in increased vinorelbine plasma levels and increased risk of neurotoxicity.</li> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>		• Strong inhibitors of CYP3A4 (e.g. itraconazole, posaconazole, voriconazole, clarithromycin) should					
<ul> <li>Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>							
<ul> <li>scheduled daily dose, no extra dose should be taken.</li> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>		neurotoxicity.					
<ul> <li>For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>		• Missed dose: If a patient misses a dose or vomits after the dose they should resume with the next					
<ul> <li>Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>		scheduled daily dose, no extra dose should be taken.					
<ul> <li>Patient Information Leaflet.</li> <li>Driving: Patients should be advised to be cautious when driving or using machines in case they experience fatigue.</li> </ul>		For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply					
experience fatigue.							
experience fatigue.		Driving: Patients should be advised to be cautious when driving or using machines in case they					
References KMCC proforma LUN-016 V7 SPC accessed online 11.09.2024							
References KMCC proforma LUN-016 V7 SPC accessed online 11.09.2024							
	References	KMCC proforma LUN-016 V7 SPC accessed online 11.09.2024					

NB For funding information, refer to CDF and NICE Drugs Funding List

Protocol No	LUN-016	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	V8	Written by	M.Archer	
Supersedes	KMCC proforma	Checked by	C.Waters	
version	V7		E.Parry	
Date	23.12.2024	Authorising consultant (usually NOG Chair)	J.Pang	

## Repeat every 21 days

TTO	Drug	Dose	Route	Directions	
Day 1	Ondansetron	8mg	РО	Take 30 minutes prior to vinorelbine dose.	
	VINORELBINE	60mg/m <sup>2</sup> Maximum 120mg	РО	OD on day 1 and 8 only Swallow whole with food Capsules available as 20mg, 30mg and 80mg	
	Dexamethasone	6mg	РО	OM for 3 days after vinorelbine dose on days 1 and 8.	
	Metoclopramide	10mg	РО	TDS for 3 days after day 1 and day 8 and then up to TDS when required. Do not take for more than 5 consecutive days	

Protocol No	LUN-016	Kent and Medway SACT Protocol		
		Disclaimer: No responsibility will be accepted for the accuracy of this information when used		
		elsewhere.		
Version	V8	Written by	M.Archer	
Supersedes	KMCC proforma	Checked by	C.Waters	
version	V7		E.Parry	
Date	23.12.2024	Authorising consultant (usually NOG Chair)  J.Pang		